Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ProQR Therapeutics NV PRQR

Healthcare Biotechnology
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is... see more

Recent & Breaking News (NDAQ:PRQR)

ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration

GlobeNewswire 11 days ago

ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

GlobeNewswire 12 days ago

ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024

GlobeNewswire December 5, 2024

ProQR Announces Third Quarter 2024 Operating and Financial Results

GlobeNewswire November 7, 2024

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

GlobeNewswire October 25, 2024

ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement

GlobeNewswire October 22, 2024

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

GlobeNewswire October 22, 2024

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society

GlobeNewswire October 7, 2024

ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference

GlobeNewswire September 10, 2024

ProQR Announces Second Quarter 2024 Operating and Financial Results

GlobeNewswire August 8, 2024

ProQR Announces Presentation on its Axiomer(TM) RNA Editing Technology at RNA Editing Summit

GlobeNewswire June 18, 2024

ProQR Announces First Quarter 2024 Operating and Financial Results

GlobeNewswire May 9, 2024

ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer(TM) RNA Editing Program Targeting NTCP for Cholestatic Diseases

GlobeNewswire May 8, 2024

ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024

GlobeNewswire April 23, 2024

ProQR Highlights Upcoming Presentations on Axiomer(TM) RNA Editing at ASGCT 27th Annual Meeting

GlobeNewswire April 22, 2024

ProQR Achieves Successful Defense of New Challenge to its Axiomer(TM) IP Portfolio

GlobeNewswire April 19, 2024

ProQR Announces Year End 2023 Operating and Financial Results

GlobeNewswire March 13, 2024

ProQR Announces Japanese Axiomer(TM) Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing

GlobeNewswire February 15, 2024

ProQR Highlights New Platform Data from Presentation on Axiomer(TM) RNA Editing Technology at Deaminet 2024

GlobeNewswire January 19, 2024

ProQR and Rett Syndrome Research Trust Join Forces with Axiomer(TM) RNA Editing Collaboration

GlobeNewswire January 5, 2024